ChoKs as a promising therapeutic target for a variety of pathologies
DOI:
https://doi.org/10.31989/bchd.v4i11.859Abstract
Alterations in cell metabolism represent a common cause of human diseases. Changes in lipid profiles are not an exception to this rule, including those lipids that are produced via the choline kinase (ChoK) pathway. ChoK catalyzes the conversion of choline to phosphocholine via the transfer of a phosphate group from ATP to choline . The formation of phosphocholine is the first step in the Kennedy pathway, which is responsible for the generation of phosphatidylcholine, a critical cell membrane component. ChoK functions as a mediator of cell growth and division and is upregulated in many types of cancers including breast cancer, pancreatic ductal adenocarcinoma, and others. A number of inhibitors have been developed that can block the activity of human ChoK (hChoK) and other eukaryotic
ChoKs, such as those found in parasites. Therefore, ChoK inhibitors (ChoKIs) are promising therapeutics, not only
for cancer [4], but for malaria and other diseases caused by parasites. This family of inhibitors are also promising therapeutics for autoimmune diseases such as rheumatoid arthritis and inflammatory conditions.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 FFC/Bioactive Compounds in Health and Disease
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request.
Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.